After failing to significantly extend survival in a confirmatory Phase 3 trial, Keytruda (pembrolizumab) will no longer be available in the U.S. for people with previously treated metastatic small ...

Tumor cell vaccines are made from cancer cells removed from a patient during surgery. These cells are then killed and altered in the lab, with the aim of increasing the potential immune response ...

The U.S. Food and Drug Administration (FDA) has approved Imfinzi (durvalumab), in combination with standard chemotherapy, as an initial treatment of people with extensive-stage small cell lung cancer ...

The immune system works to protect a person from illness by fighting foreign invaders like viruses and bacteria. It can also recognize harmful changes happening inside the body, like the formation of ...

DNX-2401 is an oncolytic immunotherapy being investigated by DNAtrix for the treatment of cancers, especially brain tumors. Oncolytic viruses, infect and destroy cancer cells while leaving normal ...

Viruses, like the flu virus, try to enter the cells in our body because they need a host to survive.Once inside, the virus begins to use the “machinery” of the cell to make copies of itself, ...

Patients with glioblastoma multiforme, a type of brain cancer, who recurred following radiation therapy and Temodal (temozolomide), did not survive longer when treated with the PD-1 inhibitor Opdivo ...

The European Commission has approved Opdivo as a second-line treatment for adults with advanced inoperable, recurrent, or metastatic esophageal squamous cell carcinoma (ESCC), who previously were ...

PF-06801591 is an immunotherapy that Pfizer is developing for several types of cancer. It is called an anti-PD-1 treatment because it blocks the PD-1 protein on the surface of immune T-cells that can ...

rSIFN-co is a potential cancer therapy that Sichuan Huiyang Life Science and Technology Corporation is developing to treat several types of advanced solid tumors.. How rSIFN-co works. rSIFN-co, or ...

The U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation to Immunocore‘s tebentafusp (IMCgp100) for HLA-A2 positive, inoperable, or advanced uveal melanoma — a common ...

A planned safety review of a Phase 2 trial evaluating MDNA55 to treat glioblastoma has shown that the drug, developed by Medicenna Therapeutics is safe to deliver precisely into a patient’s tumor, ...